Maze Therapeutics (MAZE) Assets Average (2025 - 2026)
Maze Therapeutics (MAZE) posted Assets Average of $408.4 million for Q1 2026, little changed sequentially from $409.6 million in Q4 2025, and up 42.46% YoY from $286.7 million in Q1 2025.
Powered by 
Analysis
Maze Therapeutics (MAZE) Assets Average (2025 - 2026) Analysis & Trends
Maze Therapeutics has reported Assets Average for 2 years, with the latest figure at $408.4 million in Q1 2026.
- Quarterly Assets Average rose 42.46% year-over-year to $408.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $408.4 million (up 42.46% YoY) and the FY2025 annual result came in at $318.8 million, changed N/A from the prior year.
- Assets Average was little changed at $408.4 million in Q1 2026 per MAZE's latest filing, from $409.6 million in the prior quarter.
- Over five years, Assets Average peaked at $409.6 million in Q4 2025 and troughed at $286.7 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Maze Therapeutics | 1.55 Bn | 1.55 Bn | - | 475.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 475.67 Mn |
| Mar 31, 2026 | 408.42 Mn |
| Dec 31, 2025 | 409.59 Mn |
| Sep 30, 2025 | 362.79 Mn |
| Jun 30, 2025 | 318.18 Mn |
| Mar 31, 2025 | 286.69 Mn |